Related Experiment Video
Updated: May 6, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C, stigma and cure
Rui Tato Marinho1, David Pires Barreira
1Rui Tato Marinho, David Pires Barreira, Department of Gastroenterology and Hepatology Hospital Santa Maria, Medical School of Lisbon, 1649-035 Lisboa, Portugal.
Insights
Hepatitis C virus (HCV) infection affects millions globally, often asymptomatically, leading to severe liver disease. New Direct Antiviral Agents (DAAs) offer a high cure rate, transforming treatment outcomes.
Area of Science:
- Hepatology and Viral Oncology
- Infectious Diseases Epidemiology
Background:
- Hepatitis C virus (HCV) is a major global health concern, affecting 170-200 million people worldwide.
- Chronic HCV infection often remains asymptomatic, leading to severe complications like liver cirrhosis and hepatocellular carcinoma (HCC).
- Hepatocellular carcinoma, a leading cause of cancer mortality, is increasingly linked to chronic hepatitis C in Western countries.
Discussion:
- Hepatitis C extends beyond liver pathology, encompassing significant mental, psychological, familial, and social dimensions, often exacerbated by stigma.
- Inadequate information regarding HCV transmission, consequences, and especially treatment advancements contributes to patient and healthcare provider challenges.
- The psychosocial impact of hepatitis C necessitates a comprehensive approach addressing stigma and promoting awareness of effective treatments.
Key Insights:
- HCV is an oncogenic RNA virus, with chronic infection a primary driver of hepatocellular carcinoma.
- Hepatocellular carcinoma represents the fifth leading cause of cancer mortality globally.
- Effective treatment of hepatitis C is crucial for preventing cancer development and improving patient outcomes.
Outlook:
- Hepatitis C treatment has evolved significantly from low cure rates (6% in the 1980s) to high efficacy with new Direct Antiviral Agents (DAAs).
- Current generation DAAs achieve cure rates of 80%-90%, offering a definitive elimination of the virus.
- Future efforts should focus on increasing access to diagnosis and treatment, alongside continued research into HCV eradication strategies.
Abstract:
The infection with hepatitis C virus (HCV) is one of the most important global chronic viral infections worldwide. It is estimated to affect around 3% of the world population, about 170-200 million people. Great part of the infections are asymptomatic, the patient can be a chronic carrier for decades without knowing it. The most severe consequences of the chronic infection are liver cirrhosis and hepatocellular carcinoma, which appears in 20%-40% of the patients, leading to hepatic failure and death. The HCV was discovered 25 years ago in 1989, is a RNA virus and classified by the World Health Organization as an oncogenic one. Hepatocellular carcinoma is one of the most important cancers, the fifth worldwide in terms of mortality. It has been increasing in the Ocidental world, mainly due to chronic hepatitis C. Hepatitis C is not only a liver disease and a cause of cirrhosis, but also a mental, psychological, familiar, and social disease. The stigma that the infected person sometimes carries is tremendous having multiple consequences. The main cause is lack of adequate information, even in the health professionals setting. But, besides the "drama" of being infected, health professionals, family, society and the infected patients, must be aware of the chance of real cure and total and definitive elimination of the virus. The treatment for hepatitis C has begun in the last 80's with a percentage of cure of 6%. Step by step the efficacy of the therapy for hepatitis C is rapidly increasing and nowadays with the very new medications, the so called Direct Antiviral Agents-DAAs of new generation, is around 80%-90%.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Sexually Transmitted Infections

